Gastroenterology Book



Aka: Amitiza, Lubiprostone
  1. See Also
    1. Gastrointestinal Opioid Antagonist (e.g. Methylnatrexone, Movantik, Naloxegol, Nalmedemedine)
    2. Opioid Adverse Effect Management
    3. Bowel Regimen in Chronic Narcotic Use
  2. Dosing
    1. Irritable Bowel Syndrome with Constipation: 8 mcg orally twice daily
    2. Chronic Constipation: 24 mcg orally twice daily
  3. Adverse Effects
    1. Nausea (with 24 mcg dose)
    2. Diarrhea (with 24 mcg dose)
    3. Chest Pain or Dyspnea
      1. Follows dose within 1 hour
      2. Resolves within 3 hours
  4. Disadvantages
    1. Low efficacy in Irritable Bowel Syndrome with Constipation: Only 14% respond
    2. Expensive: $200 per month
  5. Mechanism
    1. ClC(2) chloride channel opener
  6. References
    1. Chang (2006) Curr Treat Options Gastroenterol 9(4):314-23 [PubMed]
Medication Costs
amitiza (on 2/22/2017 at Medicaid.Gov Pharmacy Drug pricing)
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information.

lubiprostone (C1684405)

Definition (NCI) A bicyclic fatty acid derived from prostaglandin E1 and a chloride channel activator with laxative activity. Upon intake, lubiprostone specifically binds to and activates the type 2 chloride channel (ClC-2) in the apical membrane of the gastrointestinal epithelium. This produces an efflux of chloride ions, thereby drawing water into the gastrointestinal lumen. The resulting increased amounts of intestinal fluid soften the stool, increase motility, and improve bowel movements.
Concepts Pharmacologic Substance (T121) , Eicosanoid (T111)
MSH C506401
SnomedCT 420304008, 421856003
English Lubiprostone, Lubiprostone (product), Lubiprostone (substance), 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid, Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)-, lubiprostone (medication), lubiprostone [Chemical/Ingredient], LUBIPROSTONE, lubiprostone
Spanish lubiprostona, lubiprostona (producto), lubiprostona (sustancia)
Derived from the NIH UMLS (Unified Medical Language System)

Amitiza (C1699150)

Concepts Lipid (T119) , Pharmacologic Substance (T121)
MSH C506401
English Amitiza
Derived from the NIH UMLS (Unified Medical Language System)

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree